Plaque characterization: surrogate markers or the real thing?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Wickline, Samuel A
EP
S
o
S
S
D
c
m
t
t
d
a
(
p
s
o
h
w
a
l
d
u
u
o
d
a
a
o
d
v
m
o
a
c
i
W
p
c
r
o
v
A
Journal of the American College of Cardiology Vol. 43, No. 7, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.009a
v
l
d
a
d
t
d
a
F
u
w
m
(
i
v
h
o
(
s
l
f
h
p
s
i
s
t
m
n
o
p
v
p
t
m
e
d
r
c
t
s
c
e
t
m
s
b
i
(DITORIAL COMMENT
laque Characterization:
urrogate Markers
r the Real Thing?*
amuel A. Wickline, MD, FACC
t. Louis, Missouri
espite what we have learned about atherosclerosis and
oronary artery disease, more than 50% of cases of acute
yocardial infarction still occur unexpectedly, and many of
hese present as sudden death (1). We understand many of
he biological and environmental factors involved in the
evelopment of coronary artery disease and even have
ppreciated recently that certain time-honored risk factors
hypertension, smoking, diabetes, hyperlipidemia) are
resent in the majority of cases, which can serve as general
ignposts of its presence (2). We also recognize the potential
f certain drugs (such as aspirin, statins) to alter the natural
istory of the disease by postponing clinical sequelae.
See page 1177
Nevertheless, it is likely that acute coronary syndromes
ill continue to increase as the population at risk expands
nd ages, despite the enormous strides made in preserving
ife and reducing morbidity after an event. Coronary artery
isease is a chronic but mostly silent condition that appears
nlikely to be cured in the classical sense. If we are
ltimately to shift from an era of secondary prevention to
ne of primary prevention, other tools will be needed to
efine risk.
One key question to answer is: can we assess the risk of
cute myocardial infarction within a specified time frame for
n individual patient? For patients harboring clinically
ccult disease, this conundrum must be solved before we can
esign clinical trials focused on treating the insidious
ulnerable or unstable plaque because such trials otherwise
ight be preemptively expensive if based solely on “hard”
utcomes like death or infarction. We will need to define
nd validate new risk factors, such as lesion anatomy,
omposition, chemistry, and metabolism, which apply to
ndividuals rather than to statistical amalgams of patients.
e will need to sample the “state” of the vasculature more
recisely at specific moments in time and space. And of
ourse, we would like to do all of this noninvasively,
epeatedly, and conveniently so we can verify the efficacy of
ur interventions!
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.cFrom Washington University, St. Louis, Missouri.In response to these needs, a number of laboratories have
ccepted the challenge of molecular characterization of the
ulnerable or unstable lesion. The era of noninvasive mo-
ecular imaging and targeted therapeutics has just begun for
iagnostic cardiovascular imaging and is poised to facilitate
transition to more preventative strategies. These new tools
etect not just the mere existence of disease but quantita-
ively delineate the causative molecular constituents of
isease in time and space (3,4). Novel targeted contrast
gents are being developed for plaque characterization (5).
or example, unstable lesions might be detected with the
se of targeted contrast agents that identify fibrin deposited
ithin plaque microfissures (6), adhesion or thrombogenic
olecules expressed on endothelium of vulnerable plaques
7–11), matrix metalloproteinases in the cores of progress-
ng lesions (12), or even early angiogenic expansion of the
asa vasorum that supports plaque development (13).
Recent efforts in morphologic plaque characterization
ave taken advantage of technical innovations in the arenas
f computed tomography and magnetic resonance imaging
14). These developments follow a long history of ultra-
ound tissue characterization studies aimed at defining
esion components based on signal processing of raw radio-
requency backscatter data (15). For example, ultrasound
as been shown to identify lesion calcification, lipid content,
laque cap integrity, as well as to provide more traditional
urrogate measures of disease activity such as carotid artery
ntimal-medial thickness (16).
The clinical adoption of any of these approaches to risk
tratification of individual lesions depends in large part on
he ultimate therapeutic consequences of having such infor-
ation. Although our existing diagnostic tests, such as
uclear or echo imaging stress tests, can detect flow-limiting
bstructions, they convey no direct information about
laque biology. Even invasive cardiac catheterization pro-
ides no useful information on the biological activity of
laque. Thus, as we tiptoe into the molecular imaging arena,
he quest continues to define new noninvasive surrogate
easures of coronary disease based on characterizing ath-
rosclerotic burden elsewhere in the body.
The report by Honda et al. (17) in this issue of the Journal
escribes progress in ultrasonic interrogation of atheroscle-
osis, which has emerged out of the historical context of
lassical quantitative tissue characterization work (18). The
hrust of the work is to determine whether carotid ultra-
ound can be used as a surrogate marker to predict acute
oronary artery syndromes. The methods used in the study
ntail quantification of the energy of ultrasound backscat-
ered from selected regions of vascular tissue, which is
anaged automatically with a special kind of signal proces-
or that yields an quantitative index known as integrated
ackscatter (IB) (19,20). The magnitude of IB is governed
n part by the material properties of the tissue in question
e.g., density, compressibility) (21). Accordingly, image
ontrast is provided by tissue components with very different
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Editorial Comment April 7, 2004:1185–7hysical characteristics, such as fat, collagen, or calcium,
hich each manifest increasing levels of IB in rank order.
ecause fatty lesions generally are regarded as both more
ulnerable to rupture and more thrombogenic than are
brous ones, the propensity to acute coronary syndromes
ight be estimated with ultrasound if levels of IB could
iscriminate quantitatively among these various plaque
omponents.
The major observations in the present study are that: 1)
atients with acute coronary syndromes had carotid plaques
ith lower IB than those without such syndromes (i.e., they
ave more fatty plaques); 2) the presence of “low IB
laques” predicted more complex coronary lesions (as de-
ned by cardiac catheterization) and more coronary events;
nd 3) low IB plaques were independent predictors of bad
utcomes from coronary disease, irrespective of other risk
actors. Although it is well known that intimal-medial
hickness can be used as a surrogate for diffuse atheroscle-
osis and for monitoring the response to cholesterol lower-
ng therapy (22), the present trial shows that quantifiably
ulnerable plaques segregate together in various vascular
erritories and auger bad responses in general. These data
onfirm and extend similar earlier work by Takiushi et al
23), who studied patients with carotid artery disease and
bserved low levels of IB (i.e., fatty lesions) in carotid
rteries of patients at high risk for myocardial infarction.
A long history of quantitative ultrasound vascular tissue
haracterization aids interpretation of these conclusions.
arly work by Barzilai et al. (24) identified vascular calcifi-
ation as a source of high IB and high acoustic attenuation.
thers also have pioneered similar methods to differentiate
atty from fibrous tissues with quantitative backscatter in
itro (25). For example, IB can be used to infer changes in
laque composition from fatty to fibrous components that
ollows cholesterol lowering (e.g., 10-fold increase in IB
ithout any change in plaque dimension) (26). More recent
tudies with clinical ultrasound instruments have pursued
imilar methods to show that carotid and coronary artery
laques can be classified as fibrous or fatty with the use of
uantitative tissue characterization methods (23,27). Thus,
nother justification for clinical application of these tech-
iques is that we may be able to quantify plaque “regression”
n individual patients.
What remains to be seen is where such techniques fit
ithin the expanding panoply of noninvasive image-based
ethods for plaque characterization, or even among other
ore general serum markers of risk, such as C-reactive
rotein, Lp(a), fibrinogen, and the like. A strong commen-
ation for ultrasound is that it is already employed routinely
n vascular laboratories throughout the world for detection
f carotid stenoses. It is cheap, simple to perform, well
olerated by patients, and can have direct therapeutic con-
equences (endarterectomy) if a positive interpretation is
endered.
The quantitative ultrasound measures proposed by
onda et al. (17) could be implemented on any existingquipment with modest effort on the part of manufacturers
o that a clinical trial of sufficient power could be conducted
o decide whether this measurement is worth touting as a
oninvasive screening test for vulnerable coronary plaque.
he ease of acquiring quantitative information about plaque
tructure and composition could be a boon for the nonin-
asive longitudinal evaluation of therapies designed to
tabilize lesions by converting them from the vulnerable
atty stage to a more stable fibrous composition. Such
ethods may find complementary usage in the molecular
maging era where both the mechanisms and the local
utcomes of disease (e.g., plaque composition and morphol-
gy) could be defined with greater precision to improve
ecision making for individual patients.
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